Acute neuroleptic treatment in elderly patients without dementia

American Journal of Geriatric Psychiatry

Volumn 6, Issue 3, 1998, Pages 221-229

  Mazure, Carolyn M ^a,b   Nelson, J Craig ^a   Jatlow, Peter I ^a   Bowers Jr , Malcolm R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; LORAZEPAM; PERPHENAZINE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DRUG BLOOD LEVEL; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; MALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS;

EID: 0031863997     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-199808000-00005     Document Type: Article

References (34)

1. Tsuang M, Min Lu L, Stotsky BA, et al: Haloperidol vs. thioridazine for hospitalized psychogeriatric patients: double-blind study. J Am Geriatr Soc 1971; 19:593-600
2. Branchey MH, Lee H, Amin R, et al: High- and low-potency neuroleptics in elderly psychiatric patients. JAMA 1978; 239:1860-1862
3. Honigfeld G, Rosenblum MP, Blumenthal IJ, et al: Behavioral improvement in the older schizophrenic patient: drug and social therapies. J Am Geriatr Soc 1965; 13:57-71
4. Axelsson R, Martensson E: The concentration pattern on nonconjugated thioridazine metabolites in serum by thioridazine treatment and its relationship to physiological and clinical variables. Current Therapeutic Research 1977; 20:561-586
5. Forsman A, Ohman R: Applied pharmacokinetics of haloperidol in man. Current Therapeutic Research 1977; 21:396-411
6. Muusze RG, Vanderheeren FAJ: Plasma levels and half-lives of thioridazine and some of its metabolites. EurJ Clin Pharmacol 1977; 11:141-147
7. Aoba A, Yamaguchi N, Shido M, et al: Plasma neuroleptic levels in aged patients on various neuroleptics, in Liver and Aging. Edited by Kitani K. Amsterdam, The Netherlands, Elsevier-North Holland, 1986, pp 115-124
8. Cohen BM, Sommer BR: Metabolism of thioridazine in the elderly. J Clin Psychopharmacol 1988; 8:336-339
9. Lacro JP, Kuczenski R, Roznoski M, et al: Serum haloperidol levels in older psychotic patients. Am J Geriatr Psychiatry 1996; 4:229-236
10. Folstein MS, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
11. Mattis S: Dementia Rating Scale Manual. Odessa, FL, Psychological Assessment Resources, 1988
12. Wechsler D: Wechsler Adult Intelligence Scale-Revised. New York, The Psychological Corporation, 1981
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
14. Tyaden VR, Lankelma J, Poppe H: Anodic coulometric detection with a glassy carbonelectrode in combination with reversed-phase high-performance liquid chromatography: determination of blood levels of perphenazine and fluphenazine. J Chromatogr 1976; 125:275-286
15. Larsson M, Forsman A: A high-performance liquid Chromatographic method for the assay of perphenazine and its dealkylated metabolite in serum after therapeutic doses. Ther Drug Monit 1983; 5:225-228
16. Mazure CM, Nelson JC, Jatlow PI, et al: The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. J Clin Psychiatry 1990; 51:330-334
17. Mazure CM, Nelson JC, Jatlow PI, et al: Drugresponsive symptoms during early neuroleptic treatment. Psychiatry Res 1992; 41:147-154
18. Larsen NE, Hansen LB, Knudsen P: Quantitative determination of perphenazine and its dealkylated metabolite using HPLC. J Chromatogr 1985; 341:244-250
19. Rhoades HM, OverallJE: The semistructured PBRS interview and rating guide. Psychopharmacol Bull 1988; 24:101-104
20. Mazure CM, Cellar JS, Bowers MB Jr, et al: Assessment of extrapyramidal symptoms during acute neuroleptic treatment. J Clin Psychiatry 1995; 56:95-100
21. Hansen BL, Larsen NE, Gulmann N: Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology 1982; 78:112-115
22. Hansen BL, Larsen NE, Gulmann N: Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practices. Psychopharmacology 1985; 87:16-19
23. Kay DWK, Roth M: Environmental and hereditary factors in the schizophrenia of old age ("late paraphrenia") and their bearing on the general problem of causation in schizophrenia. Journal of Mental Science 1961; 107:649-686
24. Post F: Persistent persecutory states of the elderly. Oxford, UK, Pergamon, 1966
25. Herbert ME, Jacobson S: Late paraphrenia. Br J Psychiatry 1967; 113:461-469
26. Woerner MG, Alvir JMJ, Kane JM, et al: Neuroleptic treatment of elderly patients. Psychopharmacol Bull 1995; 31: 333-337
27. Hansen BL, Larsen NE: Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 1977; 53:127-130
28. Wilens TE, Biederman J, Baldessarini RJ, et al: Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry 1992; 31:691-698
29. Nelson JC, Bock JL, Jatlow PI: Clinical implications of 2-hydroxydesipramine plasma concentrations. Clin Pharmacol Ther 1983; 33:183-189
30. Greenblatt DJ, Divoll AI, Abernathy DR, et al: Alprazolam kinetics in the elderly: relation to antipyrine disposition. Arch Gen Psychiatry 1983; 40:287-290
31. Nelson JC, Mazure CM, Jatlow PI: Desipramine treatment of major depression in patients over 75 years of age. J Clin Psychopharmacol 1995; 15:99-105
32. Abernathy DR, Greenblatt DJ, Shader RI: Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985; 232:183-188
33. Dahl-Puustinen ML, Liden A, Aim C, et al: Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46:78-81
34. Jerling M, Dahl ML, Aberg-Wistedt A, et al: The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996; 59:423-428